SLEIMAN, J.; CHARABATY, A.; RAHMAN, A. ur. Do pharmacokinetics justify dose-optimization for loss of response to Vedolizumab in IBD?. @Gijournal, [S. l.], v. 1, n. 1, 2021. DOI: 10.52697/gijournal.v1i1.23. Disponível em: https://gijournal.org/index.php/gijournal/article/view/23. Acesso em: 11 sep. 2026.